Engineered 'starter key' for brain tumor offers new model for drug testing

Testing a new class of drugs on medulloblastoma is enabled by a gene-controlling technology called CRISPR/dCas9

Memphis, Tennessee, June 25, 2018

Two researchers in lab

Co-first authors Chunliang Li, Ph.D. (left) and BaoHan Vo, Ph.D, (right) applied CRISPR technology to activate MYC in neural cells by homing in on the promoter, which helped create medulloblastoma tumors for research study.  

Researchers at St. Jude Children’s Research Hospital have applied a new way to trigger the brain tumor medulloblastoma in neural cells that will lead to the ability to test a promising class of anti-tumor drugs. The technology they used, called CRISPR/dCas9 activation, is the equivalent of using a key to start a car, while previous approaches to producing tumors were more like bypassing the key to hot-wire the vehicle.

The interdisciplinary research team included Martine F. Roussel, Ph.D., a member in the Department of Tumor Cell Biology and co-leader of the Cancer Biology Program. The findings appeared online June 7 in the journal Scientific Reports.

Researchers studied Group 3 medulloblastoma, which is the most common aggressive subtype of medulloblastoma in children. Group 3 medulloblastoma is triggered by over-activation of a gene called MYC.

Four St. Jude researchers talking to each other at a table.

An interdisciplinary research team led by Martine F. Roussel, Ph.D. (left), applied a new way to trigger the brain tumor medulloblastoma in neural cells that will lead to the ability to test a promising class of anti-tumor drugs.

Previously scientists had generated medulloblastoma tumors in mice for drug testing by introducing a virus carrying activated MYC into neural cells. However, these mouse models bypassed critical MYC genetic controls — the biological equivalent of a car key. The problem with such “hot-wired” models was that they did not allow researchers to test a promising class of drugs called BET inhibitors that could suppress MYC by interfering with the gene’s promoter.

In their research, co-first author Chunliang Li, Ph.D. in collaboration with Jin-Ah Kwon, Ph.D. and BaoHan Vo, Ph.D, applied CRISPR technology to activate MYC in neural cells by homing in on the promoter. Many applications of the technology use CRISPR/Cas9, which is a molecular assemblage that can target a specific genetic sequence and snip it apart. However, Li used a “deficient” version, called CRISPRa/dCas9, in which the cutting ability was crippled. Instead, he engineered the assemblage to home in on the MYC promoter and switch it on.  Engineered neural cells were implanted into mice. The cells grew into tumors that were medulloblastoma. Li and Kwon work in the laboratory of co-author Charles J. Sherr, M.D., Ph.D., member and chair of the Department of Tumor Biology and a Howard Hughes Medical Institute Investigator.

A central question was whether CRISPRa/dCas9 produced tumors that exactly mimicked clinical medulloblastomas. Indeed, pathology examination of the tumors by co-author Brent Orr, M.D., Ph.D.,—using a technique called immunostaining—established that the tumors had all the characteristics of clinically occurring tumors. Also, genetic analysis by co-author David Finkelstein, Ph.D., established that the tumors were genetically identical to clinical medulloblastomas. And critically, Vo found that a BET inhibiting drug suppressed the activity of MYC in tumors.

“Our use of this technology represents the first time it has been used to induce tumor development,” Roussel said. “Now, we are using the mouse model to test BET inhibitors in various combinations with other drugs in clinical use, to determine whether we can achieve a synergy that will be effective against medulloblastoma.” Roussel said that the effective drug combinations they discover might go into clinical trials at St. Jude.

Roussel also pointed out that the CRISPRa/dCas9 technique could be readily adapted to produce mouse models of other cancers driven by over-activated MYC. These include breast, colorectal, pancreatic, gastric and uterine cancers. And in principle, the technology could be applied to any cancers to produce more accurate mouse models that utilize the natural control mechanisms for the genes driving the cancers, she said.

The other author is Beisi Xu of St. Jude.

The research was supported by the National Instituted of Health (CA-096832, CA-21765, P30CA021765-37), Howard Hughes Medical Institute, and ALSAC, the fundraising and awareness organization of St. Jude.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.